Search

Displaying results 471 - 480 of 9347 in total
  1. Drug

    Allylestrenol

    go.drugbank.com/drugs/DB01431
    Investigational

    It is widely marketed throughout Europe, including Russia and many other European countries, and is also available in Japan, Hong Kong, India, Bangladesh, Indonesia, and much of Southeast Asia, though … notably not in the United States or Canada.

    Categories: Sex Hormones and Modulators of the Genital System
  2. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  3. Drug

    MVR-C5252

    go.drugbank.com/drugs/DB30379
    Investigational

    MVR-C5252 is under investigation in clinical trial NCT06126744 (Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252).

  4. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide may be found in over-the-counter vitamin-mineral supplements as a source of [DB09130]. The mean daily dietary intake of copper in adults ranges between 0.9 and 2.2 mg [L2422]. … Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO.

    Mixtures: TL-Folate, RE Nata OB
  5. Drug

    Bexicaserin

    go.drugbank.com/drugs/DB18885
    Investigational

    Bexicaserin is under investigation in clinical trial NCT05626634 (Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy).

  6. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

  7. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

  8. Drug

    Riboflavin

    go.drugbank.com/drugs/DB00140
    ApprovedInvestigationalNutraceuticalVet approved

    The richest natural source is yeast. … It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide.

    Mixtures: Folika-T, TL-Folate
  9. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

  10. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR … Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.